In a letter from Jim McGorry, CEO of Biostage, Inc. (NASDAQ: BSTG), shareholders were updated on the company’s valuation and the outlook for the second half of 2016. Biostage is a Massachusetts-based developer of bioengineered organ implants for treating life-threatening diseases of the esophagus, bronchus, and trachea, including cancer. McGorry explained that Biostage has made […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.